| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Psychiatric Disorders | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Psychiatric Disorders | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Seaport Therapeutics, Inc.$20.45
+0.01 (+0.05%)
F 19Pipeline Score Richly Valued Pharma · Clinical
Market Cap
925.28 M
EPS
-
P/E Ratio
-
Value Trade
1.57 M
4.35 %
Week
-8.71 %
1 Month
-8.71 %
3 Month
-8.71 %
6 Month
-8.71 %
5 Year
-8.71 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
71.82 K
52 Week Range
14.85 - 19.17
% held by Insiders
67.29 %
% held by Institutions
5.22 %
Enterprise Value
1.04 B
Total Shares
52.87 M
Short %
15.87 %
Float Shares
16.97 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F19
Pipeline Score $41M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 18%
Micro Cap (rank 749 of 912)
Percentile RankSeaport Therapeutics, Inc. has significant pipeline risk (19/100), with $137M risk-adjusted pipeline value, led by SPT-300 in Major Depressive Disorder (MDD) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPT-300 Small molecule | Major Depressive Disorder (MDD) | Phase 2 | NCT07161700 | 12% | $137M | ENROLLING BY_INVITATION | 720 | FAST | D (26) | May 1, 2027 | - | LOW Jul 13, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SPTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SPTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SPTXUnlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-targeting Prodrug Technology
The article discusses a new technology aimed at enhancing oral absorption of medications for neuropsychiatry. This lymphatic-targeting prodrug technology could potentially unlock new treatment options in the field. The focus on improving drug efficacy represents a significant advancement in pharmaceutical research.
Read more →SPTXPrediction of Human Pharmacokinetic Profiles of Glyph Platform Prodrugs Using Animal and Human Data via a Semi-mechanistic Pharmacokinetic Model
The article discusses a study on predicting human pharmacokinetic profiles of Glyph platform prodrugs. It utilizes both animal and human data through a semi-mechanistic pharmacokinetic model. This research aims to enhance the understanding of drug behavior in humans based on prior animal studies.
Read more →SPTX▲ +9%on this news
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics, a company founded by PureTech, has announced positive results from its Phase 1 proof-of-concept trial of GlyphAgo™. The trial involved healthy volunteers and demonstrated encouraging data regarding the drug's safety and efficacy. These findings suggest potential for further development in the therapeutic landscape.
Read more →SPTXSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical programs for neuropsychiatric disorders. The company is actively enrolling patients in the Phase 2b BUOY-1 trial for GlyphAllo, with topline data expected in early 2027. Additionally, new data from the GlyphAgo program indicate promising safety and efficacy profiles. The recent IPO raised $260 million to support ongoing development.
Read more →SPTXSeaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics has announced positive results from a Phase 1 proof-of-concept trial for GlyphAgo™, demonstrating its safety and tolerability in healthy volunteers. The multiple-ascending dose data supports further development of the therapy. This marks a significant milestone for the company in advancing GlyphAgo™.
Read more →SPTX▼ -6.5%on this news
GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
GlyphAllo, an orally bioavailable prodrug of allopregnanolone, has shown an EEG profile indicative of GABAA positive allosteric modulation in healthy volunteers. This suggests potential therapeutic benefits in modulating GABAA receptors. The study results may pave the way for further exploration in clinical applications.
Read more →SPTXSeaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Seaport Therapeutics has announced the pricing of its upsized initial public offering, offering 14,160,000 shares at $18.00 each, totaling approximately $254.9 million. The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026. The offering is expected to close on May 4, 2026, pending customary conditions.
Read more →SPTXSeaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Seaport Therapeutics has appointed Dr. Sharon Mates, the founder and former CEO of Intra-Cellular Therapies, to its Board of Directors. Dr. Mates has a strong background in neuropsychiatry and played a key role in the commercialization of the antipsychotic CAPLYTA. Her expertise is expected to enhance Seaport's mission to develop innovative treatments for neuropsychiatric disorders.
Read more →SPTXSeaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics announced positive topline results from its Phase 1 trial of GlyphAgo, a novel prodrug of agomelatine. The trial demonstrated a significant increase in bioavailability and reduced pharmacokinetic variability. GlyphAgo was well-tolerated, with no serious adverse effects reported, paving the way for further clinical trials in generalized anxiety disorder.
Read more →SPTXPredicted Liver Safety of GlyphAgo, a Lymphatic targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
The article discusses GlyphAgo, a prodrug of Agomelatine designed to target lymphatics and enhance liver safety by avoiding first-pass metabolism. This innovative approach may lead to better therapeutic outcomes compared to traditional methods. The development of GlyphAgo is a significant advancement in drug formulation.
Read more →SPTXAn oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
The article discusses a new oral allopregnanolone prodrug that successfully bypasses liver metabolism through lymphatic transport. This advancement significantly enhances bioavailability in both animal models and human subjects. The innovative approach may lead to improved therapeutic outcomes for patients requiring this treatment.
Read more →SPTXSeaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAllo (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Seaport Therapeutics announced the publication of findings on GlyphAllo, a novel oral prodrug of allopregnanolone, in Science Translational Medicine. The study confirms its therapeutic potential in major depressive disorder (MDD) and supports the ongoing Phase 2b trial. GlyphAllo's unique formulation allows for enhanced bioavailability, making it a promising candidate for treating MDD.
Read more →SPTXSeaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
Seaport Therapeutics has received up to $15 million from ARPA-H to advance GlyphCele, an oral prodrug targeting gut lymphatic dysfunction. This innovative therapy aims to address issues linked to metabolic diseases and pancreatic cancer by restoring lymphatic function. The collaboration with Monash Institute of Pharmaceutical Sciences enhances the potential impact of this research.
Read more →SPTXFrequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
The article discusses a study on the correlation between the frequency of rater-based efficacy assessments and the magnitude of placebo responses in trials for Generalized Anxiety Disorder. The findings may provide insights into the design and interpretation of clinical trials in this area. Further details on the implications of these findings are not provided.
Read more →SPTXSeaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
Seaport Therapeutics presented a meta-analysis at the ISCTM Conference, revealing that clinician-administered assessments significantly influence placebo responses in generalized anxiety disorder trials. The study examined 22 trials and found no strong correlation with other design factors. This research builds on previous findings in major depressive disorder, emphasizing the need for optimized clinical trial designs to enhance drug development success.
Read more →SPTXSeaport Therapeutics to Participate in Upcoming Investor Conferences in February and March
Seaport Therapeutics has announced its participation in several upcoming investor conferences in February and March 2026. The conferences include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the Leerink Partners Global Healthcare Conference, and the Stifel 2026 Virtual CNS Forum. The company aims to showcase its advancements in neuropsychiatric medicines and highlight its proprietary Glyph technology platform.
Read more →SPTXSeaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Seaport Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Daphne Zohar will lead the presentation, accompanied by other co-founders. The company focuses on developing innovative neuropsychiatric medicines using its proprietary Glyph technology platform, which aims to improve oral bioavailability and reduce side effects.
Read more →SPTXGlyphCBD (SPT-310), a Lymphatic-Targeting Prodrug of Cannabidiol, Significantly Inhibits Seizure Activity in the Maximal Electroshock Seizure Model
GlyphCBD (SPT-310) has demonstrated significant inhibition of seizure activity in the Maximal Electroshock Seizure Model. This lymphatic-targeting prodrug of cannabidiol shows promise in treating seizure disorders. The results suggest a potential new therapeutic avenue for patients suffering from epilepsy.
Read more →SPTXSeaport Therapeutics Presents Data Further Validating GlyphTM Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach
Seaport Therapeutics presented preclinical data at the AES Annual Meeting, showcasing its Glyph platform's ability to enhance the oral bioavailability of cannabidiol (CBD). The findings indicate that GlyphCBD can significantly reduce seizure activity at a lower dose compared to traditional CBD formulations. This advancement suggests broader therapeutic applications and improved safety profiles for CBD and other drugs.
Read more →SPTXSeaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference
Seaport Therapeutics will present at the 2025 RBC Capital Markets Healthcare Private Company Conference on December 11, 2025. The management team will discuss the company's advancements in neuropsychiatric medicines and participate in one-on-one meetings. The presentation will be available via webcast on the company's website.
Read more →SPTXSeaport Therapeutics to Present at Stifel 2025 Healthcare Conference
Seaport Therapeutics will present at the Stifel 2025 Healthcare Conference from November 11-13, 2025. The management team is scheduled to present on November 11 at 10:00 AM EST and will also engage in one-on-one meetings. The conference aims to showcase the company's advancements in neuropsychiatric medicines.
Read more →SPTXSeaport Therapeutics to Participate in Upcoming Investor Conferences
Seaport Therapeutics announced its participation in upcoming investor conferences, including the Oppenheimer Private Life Sciences Company Showcase and the 5th Annual Needham Private Biotech and MedTech Company Forum. The management team will present and engage in one-on-one meetings with investors. The company focuses on developing novel neuropsychiatric medicines using its proprietary Glyph technology platform.
Read more →SPTXSeaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers
Seaport Therapeutics has initiated a Phase 1 study for GlyphAgo (SPT-320), an oral prodrug of agomelatine, targeting generalized anxiety disorder (GAD). This study aims to assess the safety, tolerability, and pharmacokinetics of GlyphAgo in healthy volunteers. The drug is designed to enhance absorption and minimize liver metabolism issues associated with traditional agomelatine, potentially offering a new treatment option for GAD.
Read more →SPTXSeaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Seaport Therapeutics has announced the dosing of the first patient in its Phase 2b BUOY-1 study of GlyphAllo (SPT-300) for major depressive disorder (MDD). This study aims to evaluate the efficacy and safety of GlyphAllo, a novel oral prodrug of allopregnanolone. The trial builds on promising results from earlier phases and seeks to address the significant global impact of MDD.
Read more →SPTXSPT-320, a First-in-Class Prodrug of Agomelatine that AvoidsFirst-Pass Hepatic Metabolism via Lymphatic System Absorption
SPT-320 is introduced as a first-in-class prodrug of Agomelatine, designed to bypass first-pass hepatic metabolism through absorption in the lymphatic system. This novel mechanism could potentially improve the drug's therapeutic effects. The announcement highlights the innovative nature of SPT-320 in the pharmaceutical landscape.
Read more →SPTXSeaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
Seaport Therapeutics presented promising preclinical data on SPT-320, a prodrug of agomelatine, at the SOBP Annual Meeting. The data indicate that SPT-320 significantly enhances lymphatic absorption and plasma exposure of agomelatine, potentially allowing for lower doses and reduced liver enzyme elevations. The company plans to advance SPT-320 into Phase 1 clinical trials for generalized anxiety disorder.
Read more →SPTXSeaport Therapeutics to Participate in Upcoming Investor Conferences in April
Seaport Therapeutics announced participation in two upcoming investor conferences in April. The management team will present at the 24th Annual Needham Healthcare Conference on April 7 and will also engage in one-on-one meetings. Additionally, they will participate in the Citi Biotech Private Access Day on April 24. The company focuses on developing novel neuropsychiatric medicines using its proprietary Glyph technology platform.
Read more →SPTXSeaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Seaport Therapeutics has appointed Robert J. Hombach to its Board of Directors as Audit Committee Chair. Hombach brings over 30 years of financial and operational experience in the biotech sector, having held leadership roles in notable companies. His expertise is expected to enhance Seaport's governance and support its mission in advancing neuropsychiatric medicines.
Read more →SPTXSeaport Therapeutics to Participate in Two Upcoming Investor Conferences
Seaport Therapeutics announced its participation in two upcoming investor conferences in March 2025. The management team will engage in one-on-one meetings at the Leerink Partners Global Healthcare Conference and present at the Stifel 2025 Virtual CNS Forum. This highlights the company's commitment to advancing its neuropsychiatric drug development.
Read more →SPTXClinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials
The article discusses the role of clinician-administered assessments in recent clinical trials for major depressive disorder (MDD). It highlights the influence of these assessments on placebo responses. The content suggests an ongoing exploration of methodologies in MDD trials, but does not provide specific outcomes or data.
Read more →SPTXSeaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies
Seaport Therapeutics presented a meta-analysis at the ISCTM Conference, examining how clinical trial design factors influence placebo responses in major depressive disorder (MDD) studies. The analysis of 27 trials revealed that more frequent clinician assessments correlated with higher placebo responses. This research underscores the challenges in MDD trials and the need for better design to minimize placebo effects.
Read more →SPTXOptimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport
The article discusses advancements in optimizing triglyceride prodrugs of Mycophenolic Acid (MPA), highlighting how conjugation through its phenol significantly enhances lymphatic drug transport. This improvement could lead to better delivery and efficacy of immunomodulatory therapies. The findings suggest a promising direction for future drug development.
Read more →SPTXSeaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
Seaport Therapeutics has published new research demonstrating the Glyph platform's ability to enhance lymphatic drug transport, achieving a 55% absorption rate of the immunomodulatory drug mycophenolic acid. The study highlights the impact of drug attachment points on lymphatic transport and supports the platform's versatility for various therapeutic applications. This innovation could significantly improve drug delivery and efficacy.
Read more →SPTXFirst-in-human Translation of a Biomimetic Glyceride Prodrug Platform: Enabling Avoidance of First-pass Metabolism via Lymphatic Absorption
The article discusses the first-in-human translation of a biomimetic glyceride prodrug platform. This innovative approach aims to bypass first-pass metabolism through lymphatic absorption, potentially improving drug efficacy. The research highlights the significance of this platform in enhancing therapeutic outcomes for patients.
Read more →SPTXSPT-300, a First-in-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone: Safety, Tolerability, and Clinical Pharmacology in Healthy Volunteers
The article discusses SPT-300, an innovative orally bioavailable prodrug of the neurosteroid allopregnanolone. It highlights the safety, tolerability, and clinical pharmacology of SPT-300 in healthy volunteers. This development could represent a significant advancement in neurosteroid therapies, offering new treatment avenues.
Read more →SPTXSeaport Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Seaport Therapeutics will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. CEO Daphne Zohar, along with other key executives, will discuss the company's advancements in neuropsychiatric medicines. The presentation will be available via webcast, showcasing Seaport's innovative Glyph technology platform.
Read more →SPTXA First-in-Human Phase 1 Study of SPT-300, a First-in-Class Orally Bioavailable Prodrug of the NeurosteroidAllopregnanolone That is Absorbed via the Lymphatic System
The article discusses a Phase 1 study of SPT-300, an innovative orally bioavailable prodrug of the neurosteroid allopregnanolone. This drug is notable for its absorption via the lymphatic system, marking a potential breakthrough in neurosteroid therapies. The study aims to evaluate the safety and efficacy of this novel treatment.
Read more →SPTXSPT-300, an Oral Prodrug of Allopregnanolone, Potently Reduces Salivary Cortisol Response to the Trier Social Stress Test in a Randomized, Placebo-Controlled Phase 2a Study in Healthy Participants
The article discusses the results of a Phase 2a study on SPT-300, an oral prodrug of allopregnanolone. The study demonstrated that SPT-300 significantly reduces salivary cortisol levels in response to the Trier Social Stress Test among healthy participants. This suggests its potential use in managing stress-related disorders.
Read more →SPTXSeaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Seaport Therapeutics presented additional data from its Phase 1 study of SPT-300 at the ACNP Annual Meeting. The study showed that SPT-300, an oral prodrug of allopregnanolone, was well-tolerated with mild adverse events. The pharmacodynamic activity indicated potential for chronic dosing in major depressive disorder. The results support further development in a planned Phase 2b study.
Read more →SPTXSeaport Therapeutics Adds Sandi Peterson to its Board of Directors
Seaport Therapeutics has appointed Sandi Peterson to its Board of Directors. With a robust background in life sciences and leadership roles at major companies, Peterson is expected to contribute significantly to Seaport's mission of advancing neuropsychiatric medicines. Her experience includes high-profile positions at Johnson & Johnson and Bayer, enhancing the company's strategic initiatives.
Read more →SPTXSeaport Therapeutics Names Lauren White as Chief Financial Officer
Seaport Therapeutics has appointed Lauren White as Chief Financial Officer. White, previously CFO at ImmunoGen, brings extensive experience in corporate finance and strategic partnering. Her leadership is expected to support Seaport's mission of developing innovative neuropsychiatric medicines. The company aims to address significant patient needs with its proprietary Glyph technology platform.
Read more →SPTXSeaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
Seaport Therapeutics has successfully closed a $225 million Series B financing round, led by General Atlantic, to support its pipeline of neuropsychiatric medicines. The funding will help advance key clinical milestones and enhance the capabilities of its Glyph technology platform. The company aims to develop first and best-in-class treatments for conditions like depression and anxiety.
Read more →SPTXSeaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
Seaport Therapeutics has appointed Dr. David Wheadon to its Board of Directors. Dr. Wheadon, a seasoned pharmaceutical leader, brings over 30 years of experience in regulatory affairs and clinical development. His expertise is expected to enhance Seaport's efforts in advancing its clinical-stage pipeline targeting neuropsychiatric disorders such as depression and anxiety.
Read more →SPTXSeaport Therapeutics Appoints Seasoned Executives to Management Team
Seaport Therapeutics has expanded its executive team by appointing Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D., as General Counsel. Dr. Loebel brings extensive experience in CNS drug development, while Ms. Gladstein adds over two decades of legal expertise. Their appointments are expected to bolster Seaport's efforts in advancing its neuropsychiatric medicine pipeline.
Read more →SPTXSeaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
Seaport Therapeutics presented promising data on SPT-300 at the SOBP Annual Meeting, highlighting its enhanced oral bioavailability and significant reduction in cortisol levels in a Phase 2a trial. The results suggest SPT-300's potential for treating mood and anxiety disorders, including anxious depression. The proprietary Glyph platform was validated as an effective means of drug absorption.
Read more →SPTXSeaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
Seaport Therapeutics has appointed Denice Torres, J.D., to its Board of Directors, along with Eric Green as Chief Operating Officer and Michael Chen, Ph.D., as Chief Scientific Officer. These appointments follow a successful $100 million Series A financing round aimed at developing novel neuropsychiatric medicines. Torres brings significant industry experience, while Green and Chen are expected to enhance the company's operational and scientific capabilities.
Read more →SPTXSeaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
Seaport Therapeutics has successfully closed a $100 million oversubscribed Series A financing round to advance its pipeline of novel neuropsychiatric medicines. The company, leveraging its proprietary Glyph technology, aims to enhance drug delivery and efficacy for conditions like anxiety and depression. Key appointments include Daphne Zohar as CEO and Steven M. Paul, M.D. as Chair of the Board.
Read more →SPTXMesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity
The article discusses how mesenteric lymphatic dysfunction contributes to insulin resistance, particularly in the context of obesity. It emphasizes the potential of targeting this dysfunction as a novel treatment approach. This insight could lead to innovative therapies aimed at improving metabolic health in obese patients.
Read more →SPTXTriglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport
The article discusses the development of triglyceride-mimetic prodrugs of buprenorphine, which have shown potential in enhancing oral bioavailability. This advancement is attributed to the promotion of lymphatic transport, suggesting a novel method for improving the efficacy of buprenorphine. The findings could have significant implications for drug delivery systems.
Read more →SPTXTargeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice
The article discusses a novel method for delivering mycophenolic acid specifically to the mesenteric lymph node using a triglyceride mimetic prodrug. This approach has shown to enhance gut-specific immunomodulation in mice, suggesting potential benefits for targeted therapies. The findings could lead to improved treatment strategies for gut-related conditions.
Read more →Competitive Position
How SPTX ranks across every disease it competes inCompetitive Position is a premium feature
See how SPTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial